• Title of article

    Theoretical design of a new chimeric protein for the treatment of breast cancer

  • Author/Authors

    Meysam، Soleimani نويسنده 1Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran. , , Mahnam، Karim نويسنده 2Biology Department, Faculty of Sciences, Shahrekord University, Shahrekord, I.R. Iran. , , Mirmohammad Sadeghi، Hamid نويسنده , , Sadeghi-Aliabadi، Hojjat نويسنده , , Jahanian Najafabadi، Ali نويسنده Department of Pharmaceutical Biotechnology and Isfahan Pharmaceutical Sciences Research Center School of Pharmacy, Isfahan University of Medical Science ,

  • Issue Information
    دوماهنامه با شماره پیاپی 0 سال 2016
  • Pages
    13
  • From page
    187
  • To page
    199
  • Abstract
    p28 and NRC peptides are two anticancer peptides with various mechanisms have shown to be effective against breast cancer. Therefore, it seems that construction of a chimeric protein containing the two peptides might cause synergistic cytotoxic effects. However, since the two peptides bear opposite charges, production of a chimeric protein in which the two moieties do not intervene each other is difficult. In this study, our goal was to find a suitable peptide linker for the new chimeric protein in a manner that none of the peptides intervene the other’s function. We selected some linkers with different characteristics and lengths and created a small library of the chimeric proteins harboring these linkers. Homology modeling and molecular dynamic simulation revealed that (PA)5P and (EAAAK)3 linkers can separate the p28 and NRC peptides effectively. Thus, the chimeric protein linked with (PA)5P or (EAAAK)3 linkers might show synergistic and stronger anticancer effects than the separate peptide moieties because they could exert their cytotoxic effects freely which is not influenced by the other part.
  • Journal title
    Research in Pharmaceutical Sciences
  • Serial Year
    2016
  • Journal title
    Research in Pharmaceutical Sciences
  • Record number

    2389749